Posted: December 7, 2024 at 2:50 am
FLORHAM PARK, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced that it filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024. With this filing, the Company is now current on its quarterly report filings.
See original here:
Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023
Posted: December 7, 2024 at 2:50 am
REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that it will host a conference call and webcast on Monday, December 9, 2024 at 4:30 pm EST to present data from COVALENT-103, the company’s Phase I trial of BMF-500, an investigational covalent FLT3 inhibitor developed using the proprietary FUSION™ System, in adult patients with relapsed or refractory acute leukemia.
Originally posted here:
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in...
Posted: December 7, 2024 at 2:50 am
WEST CHESTER, Pa., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced its development and commercialization partner, Torii Pharmaceutical Co. Ltd. (“Torii”), submitted a New Drug Application (“NDA”) of TO-208 (referred to as VP-102 and marketed as YCANTH® in the U.S.) for the treatment of Molluscum Contagiosum (“molluscum”) in Japan.
Posted: December 7, 2024 at 2:50 am
WALTHAM, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced that Mike Graffeo, CEO and co-founder, will delivery a company overview and conduct one-on-one meetings at the New England Venture Summit, which is being held December 10-11 in Boston, MA.
Read the original post:
FluidForm Bio™ Announces Participation in the New England Venture Summit
Posted: December 7, 2024 at 2:50 am
PARSIPPANY, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on December 3, 2024 to four new employees under Pacira’s Amended and Restated 2014 Inducement Plan as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the Compensation Committee of the Board of Directors.
Go here to see the original:
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Posted: December 7, 2024 at 2:50 am
ISS Notes Need for Significant Board Change at AIM Due to Clinical Failure and Lack of Transparency
Original post:
Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card
Posted: December 7, 2024 at 2:50 am
Live webcast on Thursday, December 12th at 4:00 PM ET
Read the rest here:
GRI Bio to Participate in the Virtual Investor Closing Bell Series
Posted: December 7, 2024 at 2:50 am
Segment featuring Dr. Charles Lapp, ME/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available here
Read more from the original source:
AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
Posted: December 7, 2024 at 2:50 am
TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) hereby announces that it has entered into an addendum to the previously announced debt-for-equity swap agreements (the "Debt Swap Agreements") with its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), pursuant to which Psyence Biomed has agreed to issue to the Company 337,750 Psyence Biomed common shares at a deemed price of US$3.88 per common share, in exchange for the discharging of the balance of Psyence Biomed's obligations due under the Debt Swap Agreements and a promissory note, dated January 25, 2024, issued by Psyence Biomed to the Company in connection with Psyence Biomed's listing of its common shares on the NASDAQ in January 2024.
Continue reading here:
Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations
Posted: December 7, 2024 at 2:50 am
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS
Go here to read the rest:
Virbac : Declaration of the number of shares and voting rights 11/2024
